Valuation : CervoMed Inc.

Market Cap 39.76M 34.3M 32.26M 29.39M 55.27M 3.77B 55.57M 381M 148M 1.92B 149M 146M 6.37B P/E 2026 *
-1.19x
P/E 2027 * -1.73x
Enterprise Value -119M -103M -96.67M -88.07M -166M -11.31B -167M -1.14B -445M -5.75B -447M -438M -19.07B EV / Sales 2026 *
-894x
EV / Sales 2027 * -94.2x
Free-Float
73.57%
Yield 2026 *
-
Yield 2027 * -
1 day-2.28%
1 week-3.02%
Current month-2.28%
1 month-0.39%
3 months-14.33%
6 months-35.59%
Current year-67.47%
1 week 2.55
Extreme 2.55
2.67
1 month 2.5
Extreme 2.5
3.2
Current year 2.13
Extreme 2.13
8.22
1 year 2.13
Extreme 2.13
10.89
3 years 1.8
Extreme 1.8
26.38
5 years 1.8
Extreme 1.8
26.38
10 years 1.8
Extreme 1.8
26.38
Manager TitleAgeSince
Chief Executive Officer 64 2023-08-15
Director of Finance/CFO 42 2024-02-29
Chief Tech/Sci/R&D Officer 49 2025-05-31
Director TitleAgeSince
Director/Board Member 64 2023-08-15
Chairman 64 2018-03-31
Director/Board Member 68 2020-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/11/26 Free

Executive/Senior Manager

30,000 0.3242%
2/11/26 Free

Chief Financial Officer

30,000 0.3242%
2/11/26 Free

General Counsel

30,000 0.3242%
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-3.02%-73.28%-55.61% 39.76M
-0.25%-0.92%+49.47%+89.45% 68.13B
+1.21%+0.80%+46.29%+85.32% 63.6B
+1.31%+1.81%+49.04%+12.07% 25.57B
-0.25%-1.92%-10.72%+436.70% 26.6B
+0.33%-10.61%+1.95%-16.27% 25.52B
-6.09%-11.19%+224.80%+351.08% 18.23B
+1.18%+1.66%+35.20%-18.67% 19.69B
-1.49%-6.35%+7.84%+540.26% 15.16B
+4.12%+0.30%+52.03%+150.18% 13.54B
Average -0.22%-3.46%+38.26%+157.45% 27.61B
Weighted average by Cap. +0.15%-2.86%+46.88%+142.30%

Financials

2026 *2027 *
Net sales 133K 115K 108K 98.56K 185K 12.65M 186K 1.28M 498K 6.44M 501K 490K 21.34M 833K 719K 676K 616K 1.16M 79.09M 1.16M 7.99M 3.11M 40.23M 3.13M 3.06M 133M
Net income -28.98M -25M -23.52M -21.43M -40.29M -2.75B -40.51M -278M -108M -1.4B -109M -106M -4.64B -41.31M -35.64M -33.52M -30.54M -57.43M -3.92B -57.74M -396M -154M -1.99B -155M -152M -6.61B
Net Debt -159M -137M -129M -117M -221M -15.08B -222M -1.52B -593M -7.67B -597M -584M -25.44B -118M -102M -95.99M -87.45M -164M -11.23B -165M -1.13B -442M -5.71B -444M -435M -18.94B
Logo CervoMed Inc.
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Employees
15
Date Price Change Volume
26-09-01 US$2.570 -2.28% 183,515
26-08-31 US$2.630 +1.15% 94,998
26-08-28 US$2.600 -1.52% 264,545
26-08-27 US$2.640 -0.38% 112,169
26-08-26 US$2.650 0.00% 93,644
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.570USD
Average target price
15.40USD
Spread / Average Target
+499.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRVO Stock